Merck Group (global rights to Sprifermin) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Asset Purch.

  • Financing Rounds
  • 1

Merck Group (global rights to Sprifermin) General Information

Description

Portfolio of global rights to Sprifermin medical drug based out of Darmstadt, Germany. The portfolio includes worldwide rights and trademark to sprifermin, a potential first-in-class disease modifying recombinant form of human fibroblast growth factor 18 that is being evaluated as a potential treatment for osteoarthritis.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • Darmstadt
  • Germany
Primary Industry
Buildings and Property
Acquirer
Corporate Office
  • Darmstadt
  • Germany

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Merck Group (global rights to Sprifermin) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Merck Group (global rights to Sprifermin)‘s full profile, request access.

Request a free trial

Merck Group (global rights to Sprifermin) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Merck Group (global rights to Sprifermin)‘s full profile, request access.

Request a free trial

Merck Group (global rights to Sprifermin) FAQs

  • Where is Merck Group (global rights to Sprifermin) headquartered?

    Merck Group (global rights to Sprifermin) is headquartered in Darmstadt, Germany.

  • What industry is Merck Group (global rights to Sprifermin) in?

    Merck Group (global rights to Sprifermin)’s primary industry is Buildings and Property.

  • Is Merck Group (global rights to Sprifermin) a private or public company?

    Merck Group (global rights to Sprifermin) is a Private company.

  • What is Merck Group (global rights to Sprifermin)’s current revenue?

    The current revenue for Merck Group (global rights to Sprifermin) is .

  • Who are Merck Group (global rights to Sprifermin)’s investors?

    Merck has invested in Merck Group (global rights to Sprifermin).

  • When was Merck Group (global rights to Sprifermin) acquired?

    Merck Group (global rights to Sprifermin) was acquired on 01-Jan-2022.

  • Who acquired Merck Group (global rights to Sprifermin)?

    Merck Group (global rights to Sprifermin) was acquired by Formation Bio.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process